Carson Wealth (CWM LLC)
CCCC icon

Carson Wealth (CWM LLC)’s C4 Therapeutics CCCC Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-146
Closed – – 5400
2025
Q3 		$0 Sell
146
-10,010
-99% -$24K ﹤0.01% 5291
2025
Q2 		$15K Sell
10,156
-4,273
-30% -$6.21K ﹤0.01% 4071
2025
Q1 		$23K Buy
+14,429
New +$43K ﹤0.01% 3556
2024
Q4 		– Sell
-1,018
Closed -$6K – 4925
2024
Q3 		$6K Buy
+1,018
New +$6.13K ﹤0.01% 3989
2023
Q4 		– Sell
-110
Closed – – 4161
2023
Q3 		$0 Sell
110
-46
-29% -$140 ﹤0.01% 4204
2023
Q2 		$0 Buy
156
+110
+239% +$354 ﹤0.01% 4193
2023
Q1 		$0 Hold
46
– – ﹤0.01% 4073
2022
Q4 		$0 Buy
+46
New +$381 ﹤0.01% 3985

Other funds holding CCCC

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Carson Wealth (CWM LLC)'s CCCC Position: Q4 2025 in Review

Carson Wealth (CWM LLC) sold out of C4 Therapeutics (CCCC) in Q4 2025, closing a stake of 146 shares.

Carson Wealth (CWM LLC) first reported a position in CCCC in Q4 2022 and held it in 8 quarters. The position peaked at $23K in Q1 2025. 101 funds tracked by Wall St. Rank hold CCCC as of Q4 2025.

  • Carson Wealth (CWM LLC) reported no remaining C4 Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Carson Wealth (CWM LLC) sold 146 C4 Therapeutics shares in Q4 2025.
  • Carson Wealth (CWM LLC) first reported a position in C4 Therapeutics in Q4 2022 and held it in 8 quarters.
  • Carson Wealth (CWM LLC)'s C4 Therapeutics position peaked at $23K in Q1 2025.
  • 101 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2025.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q4 2025, filed 26 Jan 2026.